mp9b01318_si_001.pdf (1.08 MB)
Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy
journal contribution
posted on 2020-02-24, 15:56 authored by Chen-Xi Yang, Lei Xing, Xin Chang, Tian-Jiao Zhou, Yu-Yang Bi, Zhi-Qiang Yu, Zhi-Qi Zhang, Hu-Lin JiangChemotherapy still accounts for a
large proportion of the treatments
of tumors, but the drug resistance and side effects caused by long-term
chemotherapy should not be underestimated. In this work, the drug
combination strategy has been widely developed to overcome the side
effects brought by the use of single drugs and improve the therapeutic
effect. However, in clinical applications, the co-delivery of drugs
is very difficult, and different in vivo kinetics
due to different drug properties will lead to a decrease in efficacy.
Thus, the design of novel antitumor therapeutic agents, including
new platinum agents, represents an area in need of urgent attention.
Our investigation implies a promising strategy for the design of a
platinum prodrug to enhance the treatment of breast cancer. A dual-drug
delivery nanoparticle was developed for enhanced treatment of breast
cancer based on a two-into-one co-delivery strategy. Through the synergistic
effect of released cisplatin hydrate and tolfenamic acid (COX-2 inhibitor)
from the coordination prodrug, the tumor growth is significantly suppressed,
and the survival time is greatly extended in breast tumor-bearing
mice.